Molecular therapy for polyQ disorders: from bench to clinical trials.
Trends Mol Med
; 2024 Jun 04.
Article
em En
| MEDLINE
| ID: mdl-38839514
ABSTRACT
Polyglutamine (polyQ) disorders are monogenic neurodegenerative disorders. Currently, no therapies are available for this complex group of disorders. Here, we aim to provide an overview of recent promising preclinical studies and the ongoing clinical trials focusing on molecular therapies for polyQ disorders.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article